Background. Telangiectatic matting is an unpredictable individual reaction of the patient with varicose veins after sclerotherapy, surgical or thermal ablation. It significantly worsens treatment results. It is difficult to eliminate matting with commonly used sclerosing agents. We hypothesised that the less aggressive. hypertonic glucose may be more effective in this situation. Objective — to assess the efficacy and safety of hypertonic glucose for sclerotherapy of telangiectatic matting. Material and methods. This was a prospective pilot study. The inclusion criterion was matting developed after sclerotherapy for spider veins in C1 patients. The patients underwent sclerotherapy with 75% glucose. The primary efficacy end-point was the clearance of the skin surface from matting 14 days after treatment assessed by six-point scale (from 0 to 5). The results were estimated by an independent blinded expert. Safety outcomes assessed were side-effects such as visual disturbances, headache and migraine, anaphylaxis, skin necrosis, pigmentation, telangiectatic matting and bruising. Results. Forty-seven women were included in the study. According to the independent expert the median score (interquartile range) was 3 (2—4) on 14th day. The score from 3 to 5 was observed for 2/3 patients. In 7 (15%) patients results were excellent with 100% clearing. No side-effects were recorded. Conclusions. In most cases telangiectatic matting can be successfully treated with hypertonic glucose. This agent provided safe treatment. However, a comparative study is necessary to determine benefits over other sclerosing agents.